DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07589608

Not yet recruitingPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Assets

Eloralintide / Macupatide

Listed sites

40

Recruiting sites

—

Enrollment

400

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07589608
Org study ID27844
Secondary IDW8M-MC-CWMMEli Lilly and Company
Secondary IDW8M-MC-MC01Eli Lilly and Company

Timeline

Milestones

Study first posted2026-05-15actual
Last update posted2026-06-01actual
Study start2026-06estimated (month precision)
Primary completion2027-09estimated (month precision)
Study completion2028-02estimated (month precision)

Assets

Investigational agents

EloralintideMacupatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion criteria

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

•Have type 1 diabetes or type 2 diabetes
•Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
•Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
•Have a history of acute or chronic pancreatitis
•All concomitant medications should be at a stable dose for at least 3 months prior to screening

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

6 endpoints
Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 36

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Weight

Time frame:Baseline, Week 36

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants who Achieve ≥5% Body Weight Reduction

Time frame:Week 36

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants who Achieve ≥10% Body Weight Reduction

Time frame:Week 36

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 36

BMI, change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.